Chronic kidney disease (CKD) is increasingly recognized as a global public health problem. There is now convincing evidence that CKD can be detected using simple laboratory tests, and that treatment can prevent or delay complications of decreased kidney function, slow the progression of kidney disease, and reduce the risk of cardiovascular disease (CVD). Translating these advances to simple and applicable public health measures must be adopted as a goal worldwide. Understanding the relationship between CKD and other chronic diseases is important to developing a public health policy to improve outcomes. The 2004 Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on 'Definition and Classification of Chronic Kidney Disease' represented an important endorsement of the Kidney Disease Outcome Quality Initiative definition and classification of CKD by the international community. The 2006 KDIGO Controversies Conference on CKD was convened to consider six major topics: (1) CKD classification, (2) CKD screening and surveillance, (3) public policy for CKD, (4) CVD and CVD risk factors as risk factors for development and progression of CKD, (5) association of CKD with chronic infections, and (6) association of CKD with cancer. This report contains the recommendations from the meeting. It has been reviewed by the conference participants and approved as position statement by the KDIGO Board of Directors. KDIGO will work in collaboration with international and national public health organizations to facilitate implementation of these recommendations.
treatments can prevent or delay complications of decreased kidney function, slow the progression of kidney disease, and reduce its associated CVD risk. 2, [12] [13] [14] [15] [16] [17] [18] Translating these advances to simple and applicable public health measures must be adopted as a goal worldwide. Although there is still much to learn about the impact of treatments and their optimal combinations for CKD, it is not too early to begin implementation.
Chronic diseases are now the leading causes of death worldwide. The World Health Organization (WHO) estimates that there were approximately 58 million deaths worldwide in 2005, with 35 million attributed to chronic disease. 19, 20 In developed countries and lower-middleincome developing nations, CVD and cancer were the leading causes of death. In low-income developing countries, infections remained the leading cause of death, but chronic non-communicable diseases were on the rise. The WHO report called for governments to provide leadership in addressing the projected continued increase in deaths due to chronic diseases.
While CKD is not mentioned in the 2005 WHO report, 19 it is now recognized that CKD is common in people with CVD and with CVD risk factors, and that CKD multiplies the risk for adverse outcomes in these conditions. 17 CKD is also reported to be a risk factor for adverse outcomes in other chronic diseases such as infections and cancer, 21 and should be studied in more detail. Understanding the relationship between CKD and other chronic diseases is important to develop a public health policy to improve outcomes ( Figure 2 ).
SCOPE
KDIGO is an independent non-profit foundation governed by an international Board of Directors with the stated mission to 'improve the care and outcomes of kidney disease patients worldwide through promoting coordination, collaboration and integration of initiatives to develop and implement clinical practice guidelines'. 22 The KDIGO Controversies Conference on 'Definition and Classification of Chronic Kidney Disease' was held in Amsterdam in November 2004, attended by an international group of experts, represented an important endorsement of the Kidney Disease Outcome Quality Initiative definition and classification of CKD by the international community. 4 In 2006, KDIGO convened another Controversies Conference to build on and extend the recommendations of the 2004 conference. The agenda, selected presentations, and abstracts of the meeting are posted on the KDIGO website (http://www. kdigo.org/content-cconf.htm#Public%20Health). Specifically, the conference addressed two major topics. The plenary session included presentations on CKD screening and surveillance, standardization of creatinine measurement, experience in measuring and reporting the estimated glomerular filtration rate (eGFR), implementation of albuminuria testing, revisions to the ninth International Classification of Disease, and public policy initiatives. Breakout sessions focused on CKD classification (group 1), CKD screening and surveillance (group 2), CKD, and public policy (group 3).
Associations of CKD with chronic diseases
The plenary session included presentations on the WHO perspective on chronic disease, and on associations of CKD with other chronic diseases: CVD, infections, and cancer. The model for assembling evidence to evaluate and classify CKD as a risk factor for CVD (Table 3) was the paradigm used for evaluating the association of CKD with other chronic diseases. Breakout groups focused on CVD risk factors and CVD as risk factors for CKD development and progression (group 4), and CKD as a risk factor for adverse outcomes of chronic infections (group 5) and of cancer (group 6). Each breakout group was asked to formulate both clinical and research recommendations based on evidence and opinion. The groups did not perform a systematic review or grading of available evidence. This report contains the recommendations made at the meeting and has been reviewed by the conference participants (Appendix) and approved as position statement by the KDIGO Board of Directors. These recommendations will be pursued by the KDIGO Board with the World Health Organization and other international and national public health organizations.
RECOMMENDATIONS FROM THE BREAKOUT GROUPS Group 1: Classification of CKD
CKD is a heterogeneous condition, whose clinical manifestations and course depend on the cause and type (pathology), severity, rate of progression, and comorbid conditions. The group examined the need to refine the CKD classification to include additional clinical information, to evaluate the utility of adopting a coding system, which subdivides CKD by presumed cause, and to identify key research questions that would facilitate or improve the understanding and application of the CKD classifications system worldwide. The rationale for the recommendations is that development and adoption of a consistent framework for classification of CKD will facilitate international collaborations and allow for scientific discoveries to be more readily adopted worldwide.
Recommendations
K KDIGO should not change the existing classification at this time. The classification system endorsed by KDIGO in 2004 includes severity and modality of treatment for kidney failure (Table 2 ). It is acknowledged that additional clinical information (Table 4) is required for the evaluation and management of individual cases of CKD. However, the potential benefits of adding information was thought to be outweighed by the disadvantages of increased complexity and incomplete description of an essentially heterogeneous condition. The current classification system was deemed to be clear, simple, and useful, as evidenced by its ongoing endorsement and adoption worldwide. Moreover, there was concern that further additions would detract from the attempt to maintain a simple message applicable across various disciplines and communities. There was discussion of whether albuminuria is a marker of kidney damage in non-diabetic as well as diabetic kidney disease. Data from the Heart Outcomes and Prevention Evaluation Study indicate that 'microalbuminuria' was associated with same relative risk for progression to 'clinical proteinuria' in non-diabetic and diabetic kidney diseases, 23 suggesting that the current threshold for albuminuria as a marker of kidney damage (a spot urine albumin-to-creatinine ratio 430 mg/g) is applicable to diabetic and non-diabetic kidney diseases.
K KDIGO should work with the WHO to adopt the USA modifications to ICD-9 CM and in updates to ICD-10 and subsequent revisions. It is important that coding systems capture the elements of the current classification system. The ninth version of the International Classification of Disease in the USA (ICD-9 CM) has adopted a revised coding system that incorporates the current CKD staging system. There was consensus that current (version 10) and future (version 11) iterations of ICD should incorporate and maintain this coding system so that K KDIGO should facilitate the development of a uniform 'essential data set' for description of CKD for coding purposes. There is a need to describe an essential data set for coding to ensure that a minimal amount of data is obtained on all patients identified as having CKD. Although no final recommendations were made, key elements could include the information provided in Table 4 . For research purposes, the inclusion of race, ethnicity, socio-economic status, and level of education would improve understanding the impact of CKD worldwide. The group discussed strategies for implementation of screening and surveillance for CKD in developed and developing countries. Screening is an activity, whereby persons in a defined population who are not aware of CKD are tested to detect the disease and, if present, are subsequently treated to reduce the risk of progression of CKD and its complications. Surveillance refers to an activity to provide key information on CKD, such as time, location, magnitude, and severity, in order to guide implementation of medical and public health measures to control progression of CKD and its complications. It is not known whether screening the general population would be cost-effective. 24, 25 Targeted screening should be directed at subgroups of the population who would derive the most benefit from CKD detection. Among developed and developing nations, the risk for CKD is increased in people with CVD risk factors or established CVD, in whom CKD multiplies the risk for adverse outcomes of CVD. Thus, the 'CKD subgroup' of patients with CVD and CVD risk factors constitutes a high-risk group requiring special attention. 2 As discussed by groups 5 and 6, patients with some chronic infectious diseases and cancers may also be at increased risk. In conditions where the prevalence of CKD is increased and the risk of complications due to preventable factors is high, including adjustment of drug doses to avoid toxicity, screening for CKD may be warranted. In these groups, screening for CKD could be implemented using existing infrastructures for the detection of other chronic conditions. Many countries have registries for patients treated by dialysis and transplantation. However, these programs overlook people with severe CKD who die before the onset of kidney failure or are not treated with dialysis or transplantation despite the onset of kidney failure. In principle, a In selected populations with an increased risk for glomerulonephritis, testing for hematuria should also be performed. Equations for estimating GFR should be appropriate for standardization of the serum creatinine assay and application to majority racial and ethnic groups.
Research recommendations
K Frequency of testing should be according to available guidelines and the target group to be tested. In the absence of specific recommendations, testing need not be more frequent than once per year. The group discussed the need for CKD public policy programs in developed and developing countries, and steps to implement them. In some countries, the incidence of kidney failure due to some types of CKD is stabilizing or declining, possibly reflecting early detection and treatment. 26, 27 Although the prevalence of kidney failure varies substantially throughout the world, the number of patients and the cost of providing dialysis and transplantation continue to escalate. 26, 27 Few countries have policies for CKD and most are unaware of the high prevalence of CKD, its contribution to other diseases, or its economic burden. Prevention, early detection and intervention are the more cost-effective strategies for CKD.
At the same time, costs for other chronic diseases are increasing. In developed countries, the care of patients with hypertension, diabetes and cardiovascular disease consumes a large fraction of health care resources. 27 The epidemic of obesity is expected to magnify these costs. Developing countries are now also experiencing the burden of these non-communicable diseases, even though communicable diseases are not yet under control. CKD is especially common in people with other chronic diseases and multiplies the risk for adverse outcomes and costs. Thus, public health policies for CKD must be coordinated with existing policies for other chronic diseases.
Recommendations
K Governments should adopt a public health policy for CKD.
CKD is a key component of a cluster of chronic diseases, The group reviewed a conceptual model distinguishing risk factors for development of CKD (initiation and susceptibility) and progression of CKD to later stages including kidney failure ( Figure 3 ) and attempted to make terminology more empirical in describing putative risk factors relating both to CKD and its outcomes ( Table 6 ). The concept of a 'clinical intersection' between CKD and CVD was proposed as a 'high risk state' for poor health outcomes. 29 Inter-relationships of CKD and CVD include the following: (1) common risk factors (e.g., older age, diabetes, hypertension), (2) bidirectional effects of one disease process on the progression of the other (e.g., renal artery stenosis, heart failure caused by CKD), (3) adverse effects on one disease process when investigating the other (e.g., contrastinduced acute kidney injury complicating angiography), and (4) treatment biases potentially influenced by both diseases (e.g., angiotensin converting enzyme inhibitors).
The group addressed specific questions related to CVD (myocardial infarction, heart failure, etc) and CVD risk factors (diabetes, hypertension, dyslipidemia, obesity, and smoking) as risk factors for CKD, and attempted to distinguish CVD risk factors that were responsible for susceptibility to CKD from those that might be involved in initiation and progression. Although potentially useful from a conceptual standpoint, it was generally agreed that this distinction is difficult based on existing data. Furthermore, some risk factors (e.g., hypertension and diabetes) may operate at all three levels (susceptibility, initiation, progression) with respect to CKD. The ability to distinguish risk factors for development from progression in observational studies has been complicated by the lack of data on albuminuria or other markers of kidney damage at baseline; thus it may be difficult to be confident that patients with an estimated GFR 460 ml/min/1.73 m 2 do not have kidney damage. In order to examine these issues better in future observational studies, it was recommended to classify risk factors as: (1) likely causal mechanism, (2) mechanism uncertain, or (3) likely to reflect non-causal association. K Studies of CVD should include data on the development and progression of CKD as an important health outcome (endpoint).
Research recommendations
K Studies evaluating the impact of CVD treatments should include patients with CKD.
Group 5: CKD as a risk factor for infections
The group focused on two topics: screening for CKD in chronic communicable diseases and vaccination strategies for CKD. Whereas both acute and chronic infections can influence the risk of development and progression of CKD, [30] [31] [32] [33] [34] [35] little is known of the compounding impact of CKD on the development and outcome of chronic infections.
Infection is an important cause of morbidity and mortality among patients with kidney failure, and is the second leading cause of death following CVD. 36 rates due to pneumonia and sepsis are markedly higher in dialysis patients compared with the general population ( Figure 4) . 40, 41 These observations suggest that CKD may be a risk-multiplier for acute infectious disease-associated mortality, as it is for CVD.
The course of chronic infectious diseases might be influenced by coexisting CKD. Five infectious diseases, including the human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), tuberculosis, and malaria, are estimated to affect 873 million people worldwide. 42 Table 7 summarizes the prevalence of CKD in large cohorts of individuals with these chronic infections, and where known, its association with adverse outcomes. [43] [44] [45] [46] [47] [48] [49] [50] [51] Several studies, mainly of HIV and HBV infection, have revealed a strong association of CKD with increased morbidity and mortality. CKD may increase risk by adversely affecting the host immune response; alternatively, the development and progression of CKD may be a marker of more severe infection.
Many treatment-related issues have not been addressed. The accuracy of GFR estimating equations has not been studied well in patients with chronic infectious diseases, in whom muscle wasting due to malnutrition may confound estimates based on serum creatinine. 52, 53 Clinical trials examining the safety and efficacy of novel anti-infectious drugs traditionally exclude patients with CKD; this is particularly true for HCV and HIV infections. [54] [55] [56] Recommendations K Screening for CKD in HIV. The guidelines of the Infectious Diseases Society of America for the management of CKD in HIV-infected patients recommend screening for kidney disease at the time of HIV diagnosis. 57 Tests should include
(1) a urinalysis (for hematuria and proteinuria) and (2) a measure of kidney function (creatinine to estimate GFR). If there is no initial evidence of kidney disease, screening should be repeated annually. Semi-annual monitoring of For many of the observations, the mechanism underlying their association with CKD is unclear and many of them may be involved at multiple levels in the pathogenesis of kidney disease and its outcomes. Factors that are implicated in the development, progression and complications of kidney disease are listed in the initial category in which they could potentially appear. Adapted from. kidney function and urinary markers of kidney damage is warranted for those receiving long-term drug therapy with toxicity to the kidney. Table 8 shows the increased risk of adverse outcomes of HIV infection in patients with CKD. [43] [44] [45] [46] [47] [48] Among newly diagnosed patients with HIV, positive tests for CKD might reflect HIV-associated nephropathy, other HIV-related glomerular diseases, or drug-related toxicity, 58 but might also be caused by preexisting hypertension, diabetes mellitus, or CVD. In countries with access to highly active anti-retroviral therapy, the incidence of HIV-associated nephropathy has declined by almost 75-fold. 59 However, in the emerging chronic disease phase of the AIDS epidemic, long-term survivors are likely to develop comorbid conditions including hypertension, diabetes mellitus, and cardiovascular disease. There is also evidence to suggest that the highly active anti-retroviral therapy-associated metabolic syndrome might constitute a novel CVD risk factor, potentially associated with CKD.
60,61
K Screening for CKD in HCV. The draft KDIGO clinical practice guidelines for HCV in CKD recommend screening for kidney disease at the time of HCV diagnosis and annually thereafter. Tests should include (1) a urinalysis (for hematuria and proteinuria) and (2) a measure of kidney function (serum creatinine to estimate GFR). The occurrence of glomerular disease in association with HCV infection is well established, 62, 63 and populationlevel data are now available. A cross-sectional analysis in the USA demonstrated an association between HCV seropositivity and albuminuria in people over age 40 years. 50 Among individuals older than 60 years, 46% of HCV-seropositive individuals had albuminuria compared with 24% of those who were seronegative, but there was no significant association between HCV seropositivity and low eGFR. In a cross-sectional study from Taiwan, non-diabetic subjects who were HCV seropositive had an 8.3% prevalence of X1 þ dipstick proteinuria compared with 5.1% in the seronegative group. 51 The impact of these abnormalities on outcomes remains to be determined.
K Screening for CKD in other chronic infections. There are insufficient data to recommend screening for kidney disease at the time of diagnosing HBV, tuberculosis, and malaria, particularly Plasmodium malariae. It is acknowledged that acute and chronic phases of these infections can cause CKD, [30] [31] [32] [33] that there is potential toxicity to the kidneys of drugs used to treat them, 57 and that medication dose and frequency adjustments are necessary for decreased GFR. However, there is insufficient evidence for screening and no published guidelines on the optimal timing, frequency or cost-benefit analysis of screening for CKD in these conditions. K Vaccination in CKD. All patients with CKD Stage 5D
should be vaccinated for influenza, hepatitis B, and pneumococcus. The influenza vaccine should be offered annually. Hepatitis B vaccine should be administered at the initiation of dialysis and post-vaccine serological testing should be performed. The pneumococcal vaccine should be given at least once. Patients with CKD stages 1-4 should receive the influenza, hepatitis B, and pneumococcal vaccine if high-risk factors coexist and in accord with regional immunization guidelines. Recommendations for organ transplant candidates and recipients were discussed at a recent KDIGO conference. 64 A compilation of published guidelines from selected countries on the use of these three vaccines is available on the KDIGO website (http://www.kdigo.org/ControConf/content-immunization. htm). The substantial heterogeneity of recommendations for CKD indicates the need to evaluate the evidence basis and harmonize immunization guidelines for CKD worldwide. In the general population, vaccination for these infections is generally safe and effective. The association of CKD with impaired host cellular and humoral immunity can result in suboptimal vaccine-induced immune response. 37, 65, 66 This calls for the development of a specialized immunization and monitoring program for the CKD population. Early vaccination maximizes the chance of achieving and sustaining immunity, 67 ,68 which in turn might benefit future kidney transplant recipients. Further research is needed in CKD stages 1-4 to answer these important questions.
Research recommendations
K Studies to understand the risk of CKD in patients with HIV, HCV, HBV, tuberculosis, and Plasmodium malariae:
K Determine the prevalence of CKD. K Determine the optimal timing of screening for CKD in chronic infections, the frequency of testing, the sensitivity and specificity of screening tests, and the cost-benefit relationship of this approach.
K Evaluate the accuracy of GFR estimating equations in persons with chronic infections, with a particular focus on reducing the influence of confounding factors such as muscle wasting, malnutrition, and extracellular fluid volume expansion, particularly, in the setting of chronic viral liver disease.
K Examine the interaction of coexisting co-infections with CKD on morbidity and mortality, and the impact of coexisting co-infections on progression of CKD.
K Studies of the risk of infections and the optimal use of vaccines in CKD K Determine the optimal test for the diagnosis of latent tuberculosis, particularly in endemic areas worldwide.
K Elucidate uremic factors that contribute to impaired immunity in patients with CKD, hampering effective immunization.
K Determine the efficacy and cost-effectiveness of hepatitis B and pneumococcal vaccine in earlier stages of CKD (e.g., stage 1-4)
K Examine whether due to impaired immunity CKD patients require a specific immunization program against highly preventable communicable diseases.
Group 6: CKD as risk factor for adverse outcomes of cancer
The group addressed the assessment of kidney function in subjects with cancer, occurrence of CKD in parallel to or secondary to cancer, use of kidney sparing therapies for kidney cancers, occurrence of cancer in subjects with CKD, screening for CKD in cancer, screening for cancer in subjects with CKD, outcomes of cancer treatment in subjects with CKD. Assessment of kidney function in subjects with cancer is essential for dosage adjustment of chemotherapy and for assessment of treatment toxicities. Even in early stages of cancer, there may be muscle wasting, which could affect GFR estimates based on serum creatinine. GFR estimating equations have been tested with variable results. This variability may have immediate consequence, as shown in a report comparing the use of three creatinine-based formulas in subjects with bladder cancer, in which eligibility for adjuvant chemotherapy varied many fold according to the formula that was used. 69 Use of the abbreviated modification of diet in renal disease (MDRD) Study equation has been recommended by KDIGO, but the US Food and Drug Administration recommends using the Cockcroft and Gault formula. 70 Studies in cancer patients suggest new formulas may be more accurate, but they have not been validated and evaluated adequately. 71, 72 Table 9 summarizes the prevalence of CKD in individuals with cancer, and where known, the association of CKD with adverse outcomes of cancer. Kidney disease occurring in parallel to or secondary to cancer is well described. Paraneoplastic membranous glomerulopathy is an acknowledged complication of cancer, but there is only one quantitative report for this association. 73 Reduced GFR in subjects with cancer has been reported in over half of the CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HAART, highly active anti-retroviral therapy; HR, hazard ratio; sCr, serum creatinine.
Kidney International subjects in a study from France, but this study did not clearly distinguish whether reduced GFR was related to the cause or effects of cancer. 74 Kidney disease caused by specific cancers such as multiple myeloma is well known, but accounts for less than 1% of patients treated by dialysis in the USA. Conversely, CKD occurring after chemo-or radiotherapy is known, but has not been quantified. With the improved rates of cure of many cancers, there is a potential for increased numbers of individuals with CKD as a late effect of cancer treatment.
CKD may occur after surgery for kidney cancer. Although radical nephrectomy has been the standard surgery for localized kidney cancer for many decades, partial nephrectomy has been shown to be effective for the treatment kidney tumors less than 4 cm in diameter. Recent data suggest that a significant number of subjects with kidney cancer have CKD before treatment and an even greater number are at risk to develop an eGFR o60 ml/min/1.73 m 2 in long-term followup after nephrectomy for cancer. 75 In contrast to kidney donors, patients with kidney cancer are an older patient population, often with coexistent hypertension and other chronic diseases, which may be risk factors for development of CKD following nephrectomy. Consequently, for small, incidentally discovered kidney tumors, partial nephrectomy may be indicated even in patients without CKD.
CKD was also considered as a risk factor for cancer. Occurrence of cancers in subjects with CKD is well documented for kidney and bladder cancer. 76 Acquired cysts and kidney cancers are especially frequent in subjects on long-term dialysis but also occur before the start of dialysis, 77 and the growing number of kidney transplant candidates may require screening for native kidney cancers. 78 Kidney transplantation itself is associated with susceptibility to cancers, 79 mainly skin cancers and lymphomas, which appear to be related to immunosuppression rather than to reduced kidney function.
Data from the USA showed a 30% prevalence of past or present cancer in subjects starting dialysis, which was 50% higher than that of a matched non-dialysis Medicare population, and could not be explained by bladder or kidney cancers alone. 80 It is possible that risk factors common to both cancer and kidney disease, such as smoking, diabetes and obesity, may account for this apparently high prevalence of cancers at the start of dialysis. Screening for cancer in patients with end-stage renal disease has been evaluated using decision analysis. Screening for common cancers, such as breast or colon, had a very low yield and was not recommended. 81 This is likely due to the competing risks for increased mortality in dialysis patients. In subjects with earlier stages of CKD, quantitative analyses of the benefits of cancer screening are not known.
The potential for CKD as a risk factor for adverse outcomes of cancer and its treatment was also considered. This may be evident in some conditions such as multiple myeloma but is less well established in solid tumors. Analysis of a large database from Japan showed no increase in gastric, lung, or colon cancer mortality for subjects with eGFR o60 ml/min/1.73 m 2 compared with those with higher eGFR. 82 In the Cardiovascular Health Study, a longitudinal study of older people in the USA, a significant trend toward increased mortality from cancer was reported in those subjects in the highest quartile of cystatin C values. 21 One intriguing study reported a possible lowering of cancer risk by use of converting-enzyme inhibitors. 83 Proteinuria has been linked with poor outcome in some studies of lymphoproliferative and solid malignancies. 84 Most current phase 3 trials of cancer treatments exclude subjects with impaired kidney function. Thus, comparative data are scarce. In one study, the response rates to capecitabine or 5-fluorouracil in subjects with metastatic colorectal cancer did not differ according to estimated creatinine clearance. 85 In other studies, dose adjustment of carboplatin according to kidney function, and not body surface area, greatly improved prediction of drug levels and toxicity. 86 Newer agents, including biologicals or radionuclides, may have unsuspected kidney toxicity that can only be detected by regular testing. More regular assessment of kidney function is needed in subjects with cancer. In the USA, the National Cancer Institute (NCI) Organ Dysfunction Working Group may facilitate additional studies of cancer in patients with CKD. Communication among physicians, researchers and public health officials could be improved by harmonizing the classification of severity of CKD with the KDIGO classification.
Recommendations K All cancer patients should be screened for CKD at diagnosis, at initiation, and change of cancer therapy. Tests for CKD should include (1) a urinalysis (for hematuria and CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; k, decreased.
